Abstract: The invention provides formulations for oral delivery of a therapeutic agent wherein the formulation comprises a kappa opioid receptor agonist, an oligosaccharide stabilizing agent and an optional absorption enhancer. The kappa opioid receptor agonist may be coated with, embedded in or mixed with an oligosaccharide, such as trehalose. Also provided are capsules containing the oral formulations of the kappa opioid receptor agonists, the oligosaccharide and the absorption enhancer of the invention. The invention further provides methods of manufacture of the formulations and methods of their use for the prophylaxis, inhibition and treatment of variety of kappa opioid receptor-associated diseases and conditions such as pain, pruritus and inflammation. The methods of use include administering to the mammal the formulation of the kappa opioid receptor agonist, oligosaccharide and optional absorption enhancers.

Abstract: Systems and methods for handling a plurality items by using a sorter to receive items and obtain item information and delivery destinations from the items. A run manifest is generated having an item identifier and a destination for each of the plurality of items. The run manifest data is used in a routing module to generate dynamic routes for delivering the plurality of items, and generating a sequence identifier for each of the plurality of items according to the dynamically generated routes.

Abstract: Fullerene compounds and formulations are taught as useful in reducing oxidative stress in an organism because of their antioxidant properties and REDOX balance (homeostasis) properties.

Abstract: Fullerene compounds and formulations are taught as useful in reducing oxidative stress in an organism because of their antioxidant properties and REDOX balance (homeostasis) properties.

Abstract: A control system and method for digestion of waste activated sludge (“WAS”) includes treating the WAS first at anaerobic conditions for? a fixed period of time and then at aerobic conditions for?a fixed period of time prior to either dewatering or optional anoxic conditions followed by dewatering, supplying air to initiate aerobic conditions when a predetermined set point for maximum ammonium nitrogen has been reached within the fixed anaerobic time, and initiating dewatering or optional anoxic conditions followed by dewatering when a predetermined set point for minimum ammonium nitrogen and optional standards for vector and pathogen reduction are met within the fixed aerobic time, the method and system including monitoring either consumption of soluble alkalinity or orthophosphate reduction or both for maximum orthophosphate reduction within aerobic time.

Abstract: A control system and method for digestion of waste activated sludge (“WAS”) includes treating the WAS first at anaerobic conditions for ?a fixed period of time and then at aerobic conditions for ?a fixed period of time prior to either dewatering or optional anoxic conditions followed by dewatering, supplying air to initiate aerobic conditions when a predetermined set point for maximum ammonium nitrogen has been reached within the fixed anaerobic time, and initiating dewatering or optional anoxic conditions followed by dewatering when a predetermined set point for minimum ammonium nitrogen and optional standards for vector and pathogen reduction are met within the fixed aerobic time, the method and system including monitoring either consumption of soluble alkalinity or orthophosphate reduction or both for maximum orthophosphate reduction within aerobic time.

Abstract: Endohedral metallofullerene compounds, which in water has a relaxivity of about 30 mM?1 S?1 to about 300 mM?1 S?1 and forms a dispersion in water with entities having an average hydrodynamic radius of less than about 20 nm.

Abstract: Described herein are methods for treating inflammatory disorders. The methods comprise administering to a subject in need thereof a therapeutically effective amount of a synthetically modified fullerene.

Abstract: In various embodiments, methods described herein comprise the use of water-soluble cationic fullerene derivatives for improving plant genetic transformation. Cationic Fullerene derivatives of the invention possess DNA binding and compaction activity and provide a new method to deliver DNA into plant cells for plant transformation. Water-soluble fullerene derivatives of the invention with anionic or non-polar substituents possess antioxidant (free radical scavenging) activity, provide improved yields and efficiency of plant transformation methods such as biolistic, Agrobacterium tumefaciens, or electroporation methods by limiting cellular damage and resulting cell death leading to higher yields of viable transformed cells in the process.

Abstract: Described herein are methods for treating inflammatory disorders. The methods comprise administering to a subject in need thereof a therapeutically effective amount of a synthetically modified fullerene.

Abstract: A method of identification of compounds that modulate thyroid hormone activity, and the use of such compounds and compositions thereof for such purposes are disclosed. The compounds may be selected from the group consisting of: The compounds may be prepared as pharmaceutical compositions, and may be used for the prevention and treatment of conditions that are causally related to aberrant thyroid hormone activity, such as hyperthyroidism and thyrotoxicosis.

Abstract: Described herein are synthetically modified fullerene molecules, wherein the fullerene is preferably ellipsoid in shape with an equatorial band and two opposing poles, comprising an adduct at one or both poles, at least one adduct being a hydrophobic chemical moiety capable of anchoring the fullerene on or in a lipid membrane.

Abstract: Disclosed herein are methods of inhibiting the build-up of arterial plaque in a subject in need thereof. These methods comprise administering to the subject in need thereof a therapeutically effective amount of fullerenes.

Abstract: Compositions and methods for administering a therapeutic agent to a mammal are disclosed. The compositions comprise either (i) vesicles comprising an amphiphilic substituted fullerene, wherein the therapeutic agent is present in the vesicle interior or between layers of the vesicle wall, (ii) a substituted fullerene, comprising a fullerene core and a functional moiety, wherein the therapeutic agent is associated with the substituted fullerene, or (iii) carbon nanotubes, wherein the therapeutic agent is covalently bonded to the carbon nanotubes.

Abstract: Endohedral metallofullerene compounds, which in water has a relaxivity of about 30 mM?1 S?1 to about 300 mM?1 S?1 and forms a dispersion in water with entities having an average hydrodynamic radius of less than about 20 nm.

Abstract: In various embodiments, methods described herein comprise the use of water-soluble cationic fullerene derivatives for improving plant genetic transformation. Cationic Fullerene derivatives of the invention possess DNA binding and compaction activity and provide a new method to deliver DNA into plant cells for plant transformation. Water-soluble fullerene derivatives of the invention with anionic or non-polar substituents possess antioxidant (free radical scavenging) activity, provide improved yields and efficiency of plant transformation methods such as biolistic, Agrobacterium tumefaciens, or electroporation methods by limiting cellular damage and resulting cell death leading to higher yields of viable transformed cells in the process.

Abstract: Compositions and methods for administering a therapeutic agent to a mammal are disclosed. The compositions comprise either (i) vesicles comprising an amphiphilic substituted fullerene, wherein the therapeutic agent is present in the vesicle interior or between layers of the vesicle wall, (ii) a substituted fullerene, comprising a fullerene core and a functional moiety, wherein the therapeutic agent is associated with the substituted fullerene, or (iii) carbon nanotubes, wherein the therapeutic agent is covalently bonded to the carbon nanotubes.

Abstract: Described herein are methods for treating inflammatory disorders. The methods comprise administering to a subject in need thereof a therapeutically effective amount of a synthetically modified fullerene.

Abstract: Disclosed herein are methods for treating wounds. In one embodiment, the method comprises: administering to a subject in need thereof a therapeutically effective amount of a synthetically modified fullerene of the formula Zm—F—Yn wherein F is a fullerene of formula Cp or X@Cp, the fullerene having two opposing poles and an equatorial region; Cp represents a fullerene cage having p carbon atoms, and X@CP represents such a fullerene cage having a chemical group X within the cage; Z and Y are positioned near respective opposite poles of Cp; m=1-5 and Z is a hydrophilic, lipophilic, or amphiphilic chemical moiety; n=1-5 and Y is a lipophilic chemical moiety; p=60-200 and p is an even number; and X, if present, represents one or more metal atoms within the fullerene (F), optionally in the form of a trinitride of formula Gi=1?3Hk=3?iN in which G and H are metal atoms.

Abstract: Disclosed herein are methods of treating pruritus in a subject in need thereof. A method of treating pruritus comprises administering a therapeutically effective amount of fullerenes to a subject in need thereof.